A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia
Status:
Completed
Trial end date:
2018-08-15
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and the safety when ASP1517 is
intermittently administered in Erythropoiesis Stimulating Agent (ESA)-untreated non-dialysis
chronic kidney disease patients with anemia.